Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients

Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients
A Phase 3 clinical trial will investigate the impact of adding Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel) for the treatment of ovarian cancer patients who are resistant to platinum-based chemotherapy. Details of the clinical trial will be presented June 4 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago, in a poster titled, “INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.” The U.S. Food and Drug Administration approved Novocure‘s TTFields as a noninvasive, regional treatment method for newly diagnosed glioblastoma, an aggressive type of brain cancer. TTFields disrupts cancer cell division by delivering intermediate frequency alternating electric fields and activating cells’ "suicide" programs. For ovarian cancer patients, the therapy is delivered by four electrodes placed on a woman’s torso within the region surrounding the tumor. The delivery system is portable and allows patients to maintain a regular daily routine. Previous results of preclinical models of ovarian cancer showed that TTFields, delivered at a frequency of 200 kHz, reduced the viability of cancer cells. The Phase 2 INNOVATE trial (
Subscribe or to access all post and page content.